<DOC>
	<DOC>NCT00424476</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy, safety, tolerability, and impact on quality of life of two different doses of belimumab administered in addition to standard therapy in subjects with active, autoantibody-positive systemic lupus erythematosus (SLE) disease.</brief_summary>
	<brief_title>A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus, Systemic</mesh_term>
	<mesh_term>Belimumab</mesh_term>
	<criteria>Key Clinical diagnosis of SLE by ACR criteria. Active SLE disease. Autoantibodypositive. On stable SLE treatment regimen. Key Pregnant or nursing Have received treatment with any B cell targeted therapy. Have received treatment with a biological investigational agent in the past year. Have received IV cyclophosphamide within 180 days of Day 0. Have severe lupus kidney disease. Have active central nervous system (CNS) lupus. Have required management of acute or chronic infections within the past 60 days. Have current drug or alcohol abuse or dependence. Have a historically positive test or test positive at screening for HIV, hepatitis B, or hepatitis C.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Autoimmune Diseases</keyword>
	<keyword>Lupus</keyword>
	<keyword>SLE</keyword>
	<keyword>Systemic Lupus Erythematosus</keyword>
	<keyword>Belimumab</keyword>
	<keyword>Antibodies</keyword>
</DOC>